IMNMImmunome, Inc.
$18.00+9.1% 1Y
$18.00
$15.2452 weeks$29.84
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is IMNM?
Immunome, Inc. spent more than it took in: an operating loss of $270M on $13M of revenue, 12 months to Q2 2026.
$270M
Operating loss · on $13M of revenue · 12 months to Q2 2026
- Share count, year on year
- +30%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2022 | −738020% |
| FY2023 | −781% |
| FY2024 | −3382% |
| FY2025 | −3229% |
Details›
- Operating margin12 months to Q2 2026
- −2052%
- Net margin12 months to Q2 2026
- −1929%
- Free cash flow margin
- −1662%
- R&D as % of revenue
- 1565%
- Revenue, trailing twelve months
- $13M
- Free cash flow, trailing twelve months
- −$219M
- Net income, trailing twelve months
- −$254M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks